H.C. Wainwright lowered the firm’s price target on Orchestra BioMed (OBIO) to $12 from $14 and keeps a Buy rating on the shares following the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- OBIO Upcoming Earnings Report: What to Expect?
- Orchestra BioMed initiated with a Buy at BTIG
- Promising Clinical Developments and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings
- Orchestra BioMed Highlights Strategic Initiatives and Innovations
- Orchestra BioMed Updates Executive Compensation Policies